Last year, a cancer drug, Bexarotene, was touted as a potential treatment for Alzheimer’s disease. However, four independent studies have now failed to replicate the most dramatic result of the original study: a claim that the drug could clear half the amyloid plaques in a mere 72 hours.
Still, two of the studies confirmed findings that the drug reduced levels of amyloid-beta, and one showed improved cognition in mice.
The inconsistencies suggest more research is needed. The drug is now being tested in humans.
(2013). Studies cast doubt on cancer drug as Alzheimer's treatment.